In contrast to stimulation, the inhibition of circAGO2 by shRNA spurred tumor growth in vivo since circAGO2 activity may be controlled by the inhibition of circAGO2 and HuR response; this can be accomplished with the assistance of a HuR suppressor peptide delivery [163]. The gene discussed is ELAVL1; the disease is neoplasm.